New VP of Family Support Announced

The Cystinosis Research Network welcomes Clinton Moore to the Board of Directors as VP of Family Support.

Cystinosis Art Gallery Now Available Online

The first collection of art created entirely by Cystinosis patients is now available at

2016 Spring/Summer Newsletter Released

The CRN 2016 Spring/Summer edition of the newsletter, The Cystinosis Advocate, is available now. Please go to the News/Newsletter link to view it.

KDIGO Cystinosis Conference Report Now Available

The meeting report from the Kidney Disease: Improving Global Outcomes (KDIGO) Cystinosis Controversies Conference is now published in the June issue of Kidney International and is also available at the KDIGO website as well as on the CRN website in the Article Library. Christy Greeley, CRN Executive Director, served as an patient advocacy representative and participated in the adolescent topic workgroup at the meeting held in December 2014 in Lisbon, Portugal. The report serves as an excellent update, enhancing our knowledge on the pathophysiology, diagnosis, and management of cystinosis.

Dr. Galina Nesterova Joins CRN's Medical Advisory Board

Dr. Galina Nesterova completes CRN NIH Clinical Fellowship, takes position in Vancouver, B.C.

Dr. Galina Nesterova has completed her 6 year CRN NIH Clinical Fellowship under the direction of Dr. Bill Gahl and has accepted a position at BC Children's Hospital of British Columbia, Vancouver, B.C. Patients can contact Dr. Nesterova via email at either This email address is being protected from spambots. You need JavaScript enabled to view it. or This email address is being protected from spambots. You need JavaScript enabled to view it.

The Cystinosis Research Network is indebted to Dr. Nesterova for dedicating a significant portion of her career to the treatment of hundreds of individuals with cystinosis. She has become an expert in the disorder and continues to be one of our community's greatest advocates.

We are pleased to announce that she will be joining CRN's Medical Advisory Board and will thus continue her outstanding service to the cystinosis community.

Raptor’s PROCYSBI® New Drug Submission Accepted by Health Canada with Priority Review

NOVATO, Calif., March 21, 2016 -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP) today announced that Health Canada has accepted for review its New Drug Submission (NDS) for PROCYSBI® (cysteamine bitartrate) delayed-release capsules for the treatment of nephropathic cystinosis (NC), with Priority Review status. Priority Review provides for a shortened review process of 180 days compared to a standard 300 days. Raptor estimates, based on information provided by physicians, that there are approximately 100 individuals affected by nephropathic cystinosis in Canada. PROCYSBI, a cystine depleting agent, is approved in the U.S. for the treatment of NC in adults and children ages two years and older and in all patients with NC in Europe.

“I am pleased that PROCYSBI has been accepted for review in Canada and that the review process will be expedited,” said Krishna Polu, M.D., Chief Medical Officer of Raptor Pharmaceutical Corp. “There are currently no approved cystine depleting agents in Canada and the Priority Review status by Health Canada acknowledges the urgent unmet need Canadian patients with Cystinosis have for accessing PROCYSBI.”


CRN Newsletter Signup - Popup
  1. Stay up-to-date with the latest information from the Cystinosis Research Network by joining our email list.

  2. First Name
    Invalid Input
  3. Last Name
    Invalid Input
  4. You must enter a valid email.